In January 2025, the SCCS accepted the European Commission’s mandate to assess the safety of Cannabidiol. The Scientific Committee on Consumer Safety has just published its final Scientific Advice.
Background
Cannabidiol (CBD) (CAS No.3956-29-1, EC No.689-176-3) is one of the approximately hundred naturally occurring cannabinoids found in Cannabis plants and may account for up to 40% of the plant’s extract. It is included in the CosIng with the reported functions of “skin conditioning”, “skin protecting”, “antioxidant”, “anti-sebum”, etc.
Considering the very limited available information regarding the safety of CBD in cosmetic products, and to enable the SCCS to perform a safety assessment, a call for data was launched from 1 June 2023 to 30 September 2024.
The SCCS published the preliminary version of its Scientific Advice in November 2025.
For an exhaustive background information, see the articles
• Thimerosal, Phenylmercuric salts, Cannabidiol: requests for SCCS Opinion, CosmeticOBS, 3 February 2025
• Cannabidiol: preliminary Opinion of the SCCS, CosmeticOBS, 20 November 2025
This Scientific Advice has been subject to a commenting period of min eight weeks after its initial publication (from 19 November 2025 to 21 January 2026, due to holiday period). Comments received during this period were considered by the SCCS.
Main changes occurred in SCCS comment under 3.2.1., section 3.4.3.3, 3.4.4.2, SCCS comment 3.4.5.1., SCCS comment 3.4.5.2., section 3.4.9., SCCS comment in section …
